ReviewFrontiers in physiology2021
Anti-flavivirus Properties of Lipid-Lowering Drugs.
Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.The New England journal of medicine · 2022Trial
- Triacylglycerol metabolism is a novel target to combat West Nile virus infection.Emerging microbes & infections · 2026Article
- Review
- Reciprocal control of viral infection and phosphoinositide dynamics.FEBS letters · 2026Review
- Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus.medRxiv : the preprint server for health sciences · 2026Article
- Lipids, Tetraspanins, and Exosomes: Cell Factors inViruses · 2025Review
- Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.Journal of virology · 2025Article
- Therapeutic Use ofAnimals : an open access journal from MDPI · 2025Article
- Investigating how dengue virus-induced metabolic changes affect the host immune response and how to develop Immunomodulatory strategies.Virology journal · 2025Review
- Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.Frontiers in immunology · 2025Article
- The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection.Virology journal · 2024Review
- Machine learning-based gene expression biomarkers to distinguish Zika and Dengue virus infections: implications for diagnosis.Virusdisease · 2024Article
- The endoplasmic reticulum (ER): a crucial cellular hub in flavivirus infection and potential target site for antiviral interventions.Npj viruses · 2024Review
- A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin.Microorganisms · 2024Review
- Review
- An ivermectin - atorvastatin combination impairs nuclear transport inhibiting dengue infectioniScience · 2023Article
- The dengue virus NS1 protein; new roles in pathogenesis due to similarities with and affinity for the high-density lipoprotein (HDL)?PLoS pathogens · 2023Article
- Cholesterol-Lowering Drugs as Potential Antivirals: A Repurposing Approach against Flavivirus Infections.Viruses · 2023Article
- Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents.Microorganisms · 2023Review
- Flavivirus nonstructural proteins and replication complexes as antiviral drug targets.Current opinion in virology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Flaviviruses such as dengue (DENV) and zika (ZIKV) virus are important human pathogens, an effective vaccine or antiviral treatment against them is not available. Hence, the search for new strategies to control flavivirus infections is essential. Several studies have shown that the host lipid metabolism could be an antiviral target because cholesterol and other lipids are required during the replicative cycle of different Flaviviridae family members. FDA-approved drugs with hypolipidemic effects could be an alternative for treating flavivirus infections. However, a better understanding of the regulation between host lipid metabolism and signaling pathways triggered during these infections is required. The metabolic pathways related to lipid metabolism modified during DENV and ZIKV infection are analyzed in this review. Additionally, the role of lipid-lowering drugs as safe host-targeted antivirals is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.